Form 4: Assertio CEO Granted Stock Options Post-Split

Assertio Holdings, Inc. CEO Mark L. Reisenauer was granted 26,667 stock options with an exercise price of $11.77, vesting over three years.

Summary

• Mark L. Reisenauer, CEO and Director of Assertio Holdings, Inc., was granted 26,667 stock options.
• The stock options have an exercise price of $11.77 per share.
• The transaction date for these options is March 2, 2026, and they are set to expire on March 2, 2036.
• One-third of the granted stock options are scheduled to vest on each of the first three anniversaries of the grant date, contingent upon Mr. Reisenauer's continued employment.
• The number of securities reported has been adjusted to reflect a 1-for-15 reverse stock split effected by the Issuer on December 26, 2025.
• Mr. Reisenauer did not pay any consideration for these derivative securities, as they were granted to him.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, as it indicates continued commitment from the CEO and aligns his incentives with long-term shareholder value through equity ownership.

Positives

• The grant of stock options aligns the CEO's long-term financial interests with those of shareholders, incentivizing performance.
• The vesting schedule encourages continued employment and sustained leadership from the CEO.

Future Outlook

The vesting schedule of the stock options over the next three years implies an expectation of continued employment and performance from the CEO, aligning his incentives with the company's long-term strategic goals.

Industry Context

StockSavvy.ai notes that equity grants like these are a common form of executive compensation, aligning management's interests with shareholder value creation, particularly in the pharmaceutical or specialty pharma sector where Assertio operates. This practice is widely adopted to incentivize long-term performance and retention of key executives.

Comparison to Industry Standards

• StockSavvy.ai observes that granting stock options with a 10-year term and three-year annual vesting is a standard practice in executive compensation across various industries, including pharmaceuticals.
• Companies like Pfizer or Johnson & Johnson often utilize similar long-term incentive structures for their executives, though the specific number of options and exercise price would vary based on company size, stock price, and compensation philosophy.

Stakeholder Impact

• Shareholders: Potential benefit from aligned management incentives and long-term value creation.
• Employees (CEO): Receives equity-based compensation tied to company performance and continued service.

Next Steps

• One-third of the stock options are scheduled to vest on each of the first three anniversaries of the grant date (March 2, 2027, March 2, 2028, and March 2, 2029), assuming continued employment.

Key Dates

Recommendation

The grant of stock options to the CEO is a standard executive compensation practice that aligns management's long-term interests with those of shareholders. While positive for governance and incentive structure, this single event typically does not provide sufficient new information to alter a fundamental investment thesis, hence a 'hold' recommendation is appropriate for existing investors.

Keywords

Assertio Holdings, ASRT, stock options, CEO compensation, insider transaction, Form 4, executive compensation, equity grant